Ginkgo Bioworks (DNA) announced the acquisition of Modulus Therapeutics' cell therapy platform assets, including their chimeric antigen receptor and switch receptor libraries. Modulus Therapeutics is a cell engineering company focused on the design of next-generation cell therapies for autoimmune diseases. Modulus is focused on context-responsive CAR-NK cells in autoimmunity that feed themselves off of the autoimmune microenvironment for enhanced safety and efficacy.
Ginkgo Bioworks said Modulus' assets complement its cell therapy capabilities. With the acquisition, Ginkgo looks forward to supporting its customers who are improving the performance of T-cell and NK-cell based CAR therapies.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.